EZH2 and cancer: Therapeutic preclinical and clinical studies [27,28] in cancers harboring mutations in the SWI/SNF complex subunits have recently demonstrated promising results, highlighting the fact that epigenetic regulators, such as EZH2-inhibitors, appear as a hot research topic.